文献速递心外重症与机械循环支持

LVAD相关颅内出血后抗栓治疗的逆转与恢复

Reversal and Resumption of Antithrombotic Therapy in LVAD-Associated Intracranial Hemorrhage.
PubMed 文献 · Ann Thorac Surg · 2019-02-11

该研究基于前瞻性收集的LVAD患者数据,分析颅内出血后抗栓逆转与恢复情况。405例中39例(10%)发生颅内出血,27例接受逆转治疗,8例(30%)逆转不充分;17例存活者恢复抗栓治疗。恢复华法林±抗血小板者血栓事件少于单用抗血小板者,但非致命出血事件更多。

要点

  • LVAD相关颅内出血后抗凝逆转总体安全,但逆转不充分常见(30%)。
  • 存活者恢复抗栓中位时间:抗血小板8天,华法林14天。
  • 恢复华法林±抗血小板较单用抗血小板血栓事件更少,但非致命出血更多。

核心结论

  • LVAD相关颅内出血后抗凝逆转似乎安全,但逆转不充分常见。
  • 恢复华法林±抗血小板较单用抗血小板致命与非致命血栓事件更少,但非致命出血事件更多。

研究设计与样本

  • 前瞻性收集的LVAD合并颅内出血患者数据回顾性分析。
  • 405例LVAD患者中39例(10%)发生颅内出血:23例脑实质出血、10例蛛网膜下腔出血、6例硬膜下血肿。

主要发现

  • 27例接受抗栓逆转,8例(30%)逆转不充分,其中3例在重复影像前血肿扩大或死亡。
  • 1例(4%)发生血栓并发症(深静脉血栓)。
  • 17例存活者恢复抗栓治疗,抗血小板中位8天、华法林中位14天。
  • 恢复抗栓后复发性颅内出血中位7天,缺血性卒中中位428天。
  • 单用抗血小板者(n=4)较华法林±抗血小板者(n=14)血栓事件有增多趋势(1.37 vs 0.14 事件/患者年,p=0.08),致命血栓事件(0.34 vs 0.08 事件/患者年,p=0.89);非致命出血事件率0 vs 0.34 事件/患者年(p=0.16),无致命出血事件。

临床怎么用

  • LVAD患者颅内出血后应积极逆转抗凝,并监测逆转充分性。
  • 存活者恢复抗栓时,华法林±抗血小板可能较单用抗血小板减少血栓事件,但需警惕出血风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Little data exist regarding reversal and resumption of antithrombotics after left ventricular assist device (LVAD)-associated intracranial hemorrhage. METHODS: Prospectively collected data of LVAD patients with intracranial hemorrhage were reviewed. Coagulopathy reversal agents, antithrombotic regimens, and thrombotic (venous thromboembolism, ischemic stroke, myocardial infarction) and hemorrhagic (recurrent intracranial hemorrhage, gastrointestinal bleed, anemia requiring transfusion) complications were recorded. RESULTS: Of 405 patients, intracranial hemorrhage occurred in 39 (10%): 23 intracerebral hemorrhages, 10 subarachnoid hemorrhages, and 6 subdural hematomas. Of 27 patients who received antithrombotic reversal, 8 (30%) had inadequate coagulopathy reversal, and 3 of these patients had hemorrhage expansion or died before repeat imaging. One (4%) patient had a thrombotic complication (deep vein thrombosis). Antithrombotic therapy was resumed in 17 (100%) survivors in a median time 8 days for antiplatelet agents and 14 days for warfarin. Recurrent intracranial hemorrhage occurred within a median of 7 days of antithrombotic resumption, while ischemic stroke occurred in a median of 428 days. Patients who resumed antiplatelets alone (n = 4) had a trend toward more thrombotic events (1.37 versus 0.14 events/patient-year [EPPY]; p = 0.08), including more fatal thrombotic events (0.34 EPPY versus 0.08 EPPY; p = 0.89) compared with those resuming warfarin ± antiplatelet (n = 14). Nonfatal hemorrhage event rates were 0.34 EPPY in the warfarin ± antiplatelet versus 0 EPPY in the antiplatelet-alone group (p = 0.16). No fatal hemorrhagic events occurred. CONCLUSIONS: Reversal of anticoagulation appears safe after LVAD-associated intracranial hemorrhage, though inadequate reversal was common. Resumption of warfarin ± antiplatelet was associated with fewer fatal and nonfatal thrombotic events compared with antiplatelets alone, though more nonfatal hemorrhage events occurred.

来源:Ann Thorac Surg,查看原文。版权归原作者所有。

引用

  1. Cho SM, Moazami N, Katz S, et al. Reversal and Resumption of Antithrombotic Therapy in LVAD-Associated Intracranial Hemorrhage. Ann Thorac Surg. 2019. PMID: 30763560. doi:10.1016/j.athoracsur.2019.01.016

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。